Daniel Woolery, DO
Critical Care Medicine · Sedalia, MONPI 1740620251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 33.8% of the total. 2025 is the largest year on record at $1,842, 8.1 times the $228 reported in 2019. Among critical care medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$635
- Boehringer Ingelheim$500
- GSK$482
- Jazz Pharmaceuticals Inc.$272
- Grifols USA, LLC$213
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,71095%
- Education$2595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $1,681 |
| Sanofi | 39 | $635 |
| Boehringer Ingelheim | 25 | $500 |
| GSK | 29 | $482 |
| Jazz Pharmaceuticals Inc. | 7 | $272 |
| Grifols USA, LLC | 11 | $213 |
| Veran Medical Technologies, Inc. | 2 | $131 |
| Mylan Specialty L.p. | 7 | $110 |
| Regeneron Healthcare Solutions, Inc. | 3 | $103 |
| Dexcom, Inc. | 4 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Inari Medical, Inc. | 1 | $96 |
| Genentech USA, Inc. | 6 | $93 |
| Actelion Pharmaceuticals US, Inc. | 1 | $78 |
| Viatris Specialty LLC | 3 | $74 |
| Insmed, Inc. | 3 | $58 |
| Verona Pharma, Inc. | 3 | $58 |
| Pfizer | 3 | $42 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Novartis | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,969 in reported general payments places this provider in the 90th percentile of 208 critical care medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $347,882 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 26 | $256,888 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 170 | $127,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $77,594 |
| Dupixent PenDupilumab | 15 | $71,907 |
| Spiriva RespimatTiotropium Bromide | 68 | $46,640 |
| SymbicortBudesonide/Formoterol Fumarate | 89 | $26,201 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $20,944 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $14,698 |
| Spiriva HandihalerTiotropium Bromide | 20 | $14,564 |
| EliquisApixaban | 15 | $14,250 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $14,177 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 31 | $13,299 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,426 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $12,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $500 | $415,466134 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,681 | $167,042290 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $482 | $118,895166 claims |
| PfizerEliquis | $42 | $14,25015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 208 critical care medicine providers in Missouri.
Other critical care medicine in Sedalia
- Jacob KeepermanSaint Louis$51K
- Farid SadakaSaint Louis$41K
- Rajat DharSaint Louis$31K
- Pratik SinhaSaint Louis$25K
- Bryan KraftSaint Louis$24K
- Yuji ObaColumbia$14K
- Tinashe MadukeColumbia$13K
- Stephanie WhitbeyColumbia$12K
- Harjyot SohalOsage Beach$10K
- Adam MaySaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.